

B. K. Warren and E. E. Knaus*

Faculty of Pharmacy and Pharmaceutical Sciences,
University of Alberta,
Edmonton, Alberta T6G 2N8, Canada
Received March 29, 1982


The 1,3-dipolarcycloaddition reaction of 1-methyl-1,2,3,4-tetrahydropyridine (**1**) with organic azides **2** affords 1-methylpiperidylidene-2-sulfon(cyan)amides **4** in high yield. The reaction proceeds *via* a 2,3,4,9-tetraazabicyclo[4.3.0]non-3-ene intermediate. Acid hydrolysis of **4d** gives rise to 1-methyl-2-piperidone.

J. Heterocyclic Chem., **19**, 1259 (1982).

Reaction of 1-methyl-1,2,5,6-tetrahydropyridine with potassium *t*-butoxide in dimethyl sulfoxide affords 1-methyl-1,2,3,4-tetrahydropyridine (**1**) (**1**). The 1,3-dipolar cycloaddition reaction of the enamine **1** with organic azides **2** now provides a facile route to the pharmacologically interesting 1-methylpiperidylidene-2-sulfon(cyan)amides **4**.

A typical reaction involves the dropwise addition of a solution of methanesulfonyl azide **2a** (1 equivalent) in dry ether (10 ml) to a solution of 1-methyl-1,2,3,4-tetrahydropyridine (**1**) (1 equivalent) in dry ether (20 ml) at 25° with stirring. The reaction proceeds rapidly with evolution of nitrogen gas to yield 1-methylpiperidylidene-2-methanesulfonamide (**4a**) (82%). Under similar conditions **2b** gave

2H multiplet at 2.93-3.24 attributed to C₃-H, two 3H singlets at 3.02 and 3.06 due to NCH₃ and SO₂CH₃, and a complex 4H multiplet at 1.85 attributed to the C₄-H and C₅-H. No product resulting from the rearrangement of **3** to give 1-methylpiperidylidene-3-sulfon(cyan)amides **5** was observed since the C₂-H of **5** would be expected to absorb at a lower field than 3.39. Acid hydrolysis of **4d** using a 10% sulfuric acid/methanol solution (1:10) (**3**) gave rise to 1-methyl-2-piperidone (**6**) (55%) thus providing additional evidence in support of structures **4**. The ir and pmr spectra of **6** were identical with that of an authentic sample (4,5).



4b (71%) and **2c** gave **4c** (79%). Addition of cyanogen azide **2d** (1 equivalent) in dry acetonitrile (47 ml) to a solution of the enamine **1** (1 equivalent) in dry acetonitrile (15 ml) under an atmosphere of nitrogen affords 1-methylpiperidylidene-2-cyanamide (**4d**) (81%) (2). The mass spectrum of **4a** exhibited a molecular ion at *m/e* 190 (*M*⁺ Calcd. for C₇H₁₄N₂O₂³²S: 190.0776; Found: 190.0787) while the ir spectra displayed peaks at 1590 (C=N), 1270 (SO₂) and 1130 (SO₂) cm⁻¹. The pmr spectrum (δ) exhibited a complex 2H multiplet at 3.39 due to the C₆-H, a complex

If the intermediate triazoline adduct formed is the product of electronic control the nitrogen atom bearing the sulfono(cyano) group should be directed to the carbon of the double bond bearing the enamine ring nitrogen (6). Loss of nitrogen from the triazoline intermediate may occur by two possible mechanisms. The triazoline intermediate could eliminate nitrogen to afford the unstable 2,7-diazabicyclo[4.1.0]heptane (**3**) which then rearranges to give the stable **4** (Path A). Alternatively the triazoline adduct may fragment by a loss of nitrogen with concomitant rearrangement to yield **4** (Path B) (7). There is precedence for intermediate **3** since treatment of 1-methyl-1,4-dihydropyridine with **2a** gave 2-methyl-7-methanesulfonyl-2,7-diazabicyclo[4.1.0]hept-3-ene (**7**) in

quantitative yield (8) and subsequent reduction of 7 using 10% Palladium-on-charcoal and hydrogen gas affords 4a (9).

The reaction of other organic azides with 1-methyl-, 1-alkyl- and 1-araalkyl-1,2,3,4-tetrahydropyridines are now in progress to broaden the scope of this reaction. The broad spectrum pharmacological screening of 4a, 4b, 4c and 4d is currently in progress. Preliminary results indicate that compounds 4 exhibit significant analgesic activity. For example, 4d exhibits an ED₅₀ of 6 mg/kg in the analgesic phenylquinone writhing assay relative to an ED₅₀ of 50 for Aspirin (10).

Acknowledgements.

We are grateful to the Medical Research Council of Canada (MA-4888) for financial support of this work and

to the Alberta Heritage Foundation for Medical Research for a Studentship to B. K. Warren.

REFERENCES AND NOTES

- (1) P. Becker and F. W. Fowler, *J. Org. Chem.*, **45**, 1336 (1980).
- (2) All products gave microanalytical results within $\pm 0.3\%$ of theoretical values.
- (3) T. A. Ondrus, E. E. Knaus and C. S. Giam, *J. Heterocyclic Chem.*, **16**, 409 (1979).
- (4) Aldrich Library of IR Spectra.
- (5) Aldrich Library of NMR Spectra.
- (6) J. F. Stephen and E. Marcus, *J. Heterocyclic Chem.*, **6**, 969 (1969).
- (7) A. C. Ritchie and M. Rosenberger, *J. Chem. Soc., C*, 277 (1968).
- (8) B. K. Warren and E. E. Knaus, *J. Med. Chem.*, **24**, 462 (1981).
- (9) B. K. Warren and E. E. Knaus, Unpublished results.
- (10) H. O. Collier, L. C. Dineen, C. A. Johnson and C. Schneider, *Brit. J. Pharmacol. Chemotherap.*, **32**, 295 (1968).